Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.
Prostate cancer statistics
New cases of prostate cancer, 2014-2016 average, UK
Deaths from prostate cancer, 2016, UK
Survive prostate cancer for 10 or more years, 2010-11, England and Wales
Preventable cases of prostate cancer are not known as it is not clearly linked to any preventable risk factors
- There are around 47,700 new prostate cancer cases in the UK every year, that's around 130 every day (2014-2016).
- In males in the UK, prostate cancer is the most common cancer, with around 47,600 new cases in 2016.
- Prostate cancer accounts for 26% of all new cancer cases in males in the UK (2016).
- Prostate cancer accounts for 13% of all new cancer cases in females and males combined in the UK (2016).
- Incidence rates for prostate cancer in the UK are highest in males aged 90+ (2013-2015).
- Since the early 1990s, prostate cancer incidence rates have increased by more than two-fifths (44%) in males in the UK.
- Over the last decade, prostate cancer incidence rates have increased by around a twentieth (6%) in males in the UK.
- Around 4 in 10 prostate cancer cases are diagnosed at a late stage in England (2014) and Northern Ireland (2010-2014).
- Around 6 in 10 prostate cancer cases are diagnosed at a late stage in Scotland (2013-2014)
- Incidence rates for prostate cancer are projected to rise by 12% in the UK between 2014 and 2035, to 233 cases per 100,000 males by 2035.
- Prostate cancer in England is less common in males living in the most deprived areas.
- Prostate cancer is most common in Black males, then White males and least common in Asian males.
- An estimated 280,500 men who had previously been diagnosed with prostate cancer were alive in the UK at the end of 2010.
- There are around 11,500 prostate cancer deaths in the UK every year, that's 31 every day (2014-2016).
- In males in the UK, prostate cancer is the 2nd most common cause of cancer death, with around 11,600 deaths in 2016.
- Prostate cancer accounts for 13% of all cancer deaths in males in the UK (2016).
- Mortality rates for prostate cancer in the UK are highest in males aged 90+ (2014-2016).
- Since the early 1970s, prostate cancer mortality rates have increased by around a fifth (19%) in males in the UK.
- Over the last decade, prostate cancer mortality rates have decreased by more than a tenth (12%) in males in the UK.
- Mortality rates for prostate cancer are projected to fall by 16% in the UK between 2014 and 2035, to 48 deaths per 100,000 males by 2035.
- Prostate cancer deaths in England are not associated with deprivation.
- More than 8 in 10 (84%) men diagnosed with prostate cancer in England and Wales survive their disease for ten years or more (2010-11).
- Almost 9 in 10 (85%) men diagnosed with prostate cancer in England and Wales survive their disease for five years or more (2010-11).
- Almost 95% (94%) of men diagnosed with prostate cancer in England and Wales survive their disease for one year or more (2010-11).
- Prostate cancer survival in England is higher for men diagnosed aged 60-69 years old, probably because of PSA testing detecting latent, earlier, slow-growing cancers (2009-2013).
- Almost 95% of men in England diagnosed with prostate cancer aged 50-59 or 60-69 survive their disease for five years or more, compared with two thirds of men diagnosed aged 80 and over (2009-2013).
- Prostate cancer survival is improving and has tripled in the last 40 years in the UK, probably because of PSA testing.
- In the 1970s, a quarter of men diagnosed with prostate cancer survived their disease beyond ten years, now it's more than 8 in 10.
- When diagnosed at its earliest stage, all men with prostate cancer will survive their disease for five years or more, compared with less than a third of men when diagnosed at the latest stage.
- Five-year relative survival for prostate cancer in men is below the European average in England, Wales and Scotland but similar to the European average in Northern Ireland.
- A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- 1 in 6 UK males will be diagnosed with prostate cancer in their lifetime.
- Prostate cancer is not clearly linked to any preventable risk factors.
- No modifiable factors have been conclusively linked with prostate cancer risk, though many factors have been studied. Use of PSA testing often makes interpretation of evidence difficult.
- 'Two-week wait' is the most common route to diagnosing prostate cancer.
- GP referral is the route with the highest proportion of cases diagnosed at an early stage, for prostate cancer.
- ‘Two-week wait’ standards are met by all countries, ‘31-day wait’ and ‘62 day wait’ are not met by any country for urological cancers.
- 15% of patients diagnosed with prostate cancer have surgery to remove the tumour as part of their primary cancer treatment.
- 30% of patients diagnosed with prostate cancer have radiotherapy as part of their primary cancer treatment
- 3% of patients diagnosed with prostate cancer have chemotherapy as part of their primary cancer treatment.
The latest statistics available for prostate cancer in the UK are; incidence 2015, mortality 2016 and survival 2010-2011 (all ages combined) and 2009-2013 (by age).
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2012-2013. Staging proportions only include patients with a known stage (cases with an unknown stage at diagnosis are not included in the denominator).
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Prostate cancer is part of the group 'Urological cancer' for cancer waiting times data. Codes vary per country but broadly include: penis, prostate, testis, other and unspecified male genital organs, kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs, secondary cancers of kidney, renal pelvis, bladder and other unspecified urinary organs.
Cancer surgical resection rates data is for patients diagnosed in England between 2006 and 2010.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.
When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or
We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.